Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
PR Newswire —
First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) management Hong Kong will serve as Hua Medicine's launchpad for international market expansion SHANGHAI and HONG KONG, March 3, 2026 /PRNewswire/ -- Hua...